GWO Stock Analysis: Great-West Lifeco | TO
Insurance - Life | TO, Canada | Market Cap: 81.678m CAD | 12M Return: 61.8% | CA39138C1068 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 65.0M
EPS Trend: 96.7%
Qual. Beats: 5
Rev. Trend: -10.3%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality
Great-West Lifeco is a Canadian life and health insurer and financial services company operating in Canada, the United States, and Europe. Its businesses span insurance, retirement savings and income products, wealth and asset management, and reinsurance, serving individuals, employers, institutions, and other insurers.
Its products are sold under the Empower, Canada Life, and Irish Life brands through advisors, brokers, financial institutions, and other distribution partners. Like other insurers, it collects premiums and invests assets to help fund future claims and benefits; its asset management business also serves institutional clients. Great-West Lifeco was founded in 1979 and is a subsidiary of Power Financial Corporation.
- Empower’s U.S. retirement growth boosts fee income and earnings
- Interest-rate shifts reshape annuity spreads, investment income, and demand
- Strong capital generation supports dividend growth and share repurchases
| Net Income: 4.63b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.08 > 1.0 |
| NWC/Revenue: 109.9% < 20% (prev 108.8%; Δ 1.10% < -1%) |
| CFO/TA 0.00 > 3% & CFO 4.22b > Net Income 4.63b |
| Net Debt (-16.9b) to EBITDA (6.45b): -2.62 < 3 |
| Current Ratio: 6.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (903.5m) vs 12m ago -3.15% < -2% |
| Gross Margin: 42.74% > 18% (prev 37.85%; Δ 4.89% > 0.5%) |
| Asset Turnover: 4.21% > 50% (prev 4.90%; Δ -0.69% > 0%) |
| Interest Coverage Ratio: 16.83 > 6 (EBIT TTM 5.87b / Interest Expense TTM 349.0m) |
| A: 0.04 (Total Current Assets 48.8b - Total Current Liabilities 8.04b) / Total Assets 946b |
| B: 0.02 (Retained Earnings 17.7b / Total Assets 946b) |
| C: 0.01 (EBIT TTM 5.87b / Avg Total Assets 880b) |
| D: 0.03 (Book Value of Equity 31.3b / Total Liabilities 911b) |
| Altman-Z'' = 0.42 = B |
| DSRI: 3.0 (Receivables 22.6b/5.78b, Revenue 37.1b/40.0b) |
| GMI: 0.89 (GM 37.85% / 42.74%) |
| AQI: 1.01 (AQ_t 0.95 / AQ_t-1 0.94) |
| SGI: 0.93 (Revenue 37.1b / 40.0b) |
| TATA: 0.00 (NI 4.63b - CFO 4.22b) / TA 946b) |
| Beneish M = -1.53 (Cap -4..+1) = CCC |
As of October 21, 2026, the stock is trading at CAD 90.35 with a total of 421,288 shares traded. Over the past week, the price has changed by +0.86%, over one month by -4.62%, over three months by -0.76% and over the past year by +61.82%.
Current recommended Stop Loss: 87.70 (which is 2.9% or 1.4 ATR below the current price).
Great-West Lifeco has no consensus analysts rating.
P/E Trailing = 18.8124
P/E Forward = 14.6628
P/S = 2.2426
P/B = 2.947
P/EG = 1.7699
Revenue TTM = 37.1b CAD
EBIT TTM = 5.87b CAD
EBITDA TTM = 6.45b CAD
Long Term Debt = 8.96b CAD (from longTermDebt, last quarter)
Short Term Debt = 648.0m CAD (from shortTermDebt, last fiscal year)
Debt = 9.31b CAD (from shortLongTermDebtTotal, last quarter) + Leases 344.0m
Net Debt = -16.9b CAD (calculated: Debt 9.31b - CCE 26.2b)
Enterprise Value = 64.8b CAD (81.7b + Debt 9.31b - CCE 26.2b)
Interest Coverage Ratio = 16.83 (Ebit TTM 5.87b / Interest Expense TTM 349.0m)
EV/FCF = 15.36x (Enterprise Value 64.8b / FCF TTM 4.22b)
FCF Yield = 6.51% (FCF TTM 4.22b / Enterprise Value 64.8b)
FCF Margin = 11.37% (FCF TTM 4.22b / Revenue TTM 37.1b)
Net Margin = 12.49% (Net Income TTM 4.63b / Revenue TTM 37.1b)
Gross Margin = 42.74% ((Revenue TTM 37.1b - Cost of Revenue TTM 21.2b) / Revenue TTM)
Gross Margin QoQ = 27.00% (prev 46.88%)
Tobins Q-Ratio = 0.07 (Enterprise Value 64.8b / Total Assets 946b)
Interest Expense / Debt = 3.75% (Interest Expense 349.0m / Debt 9.31b)
Taxrate = 14.09% (780.0m / 5.54b)
NOPAT = 5.04b (EBIT 5.87b * (1 - 14.09%))
Current Ratio = 6.07 (Total Current Assets 48.8b / Total Current Liabilities 8.04b)
Debt / Equity = 0.30 (Debt 9.31b / totalStockholderEquity, last quarter 31.3b)
Debt / EBITDA = -2.62 (Net Debt -16.9b / EBITDA 6.45b)
Debt / FCF = -4.0 (Net Debt -16.9b / FCF TTM 4.22b)
Total Stockholder Equity = 29.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.53% (Net Income 4.63b / Total Assets 946b)
RoE = 15.48% (Net Income TTM 4.63b / Total Stockholder Equity 29.9b)
RoCE = 15.10% (EBIT 5.87b / Capital Employed (Equity 29.9b + L.T.Debt 8.96b))
RoIC = 0.54% (NOPAT 5.04b / Invested Capital 937b)
WACC = 5.64% (E(81.7b)/V(91.0b) * Re(5.92%) + D(9.31b)/V(91.0b) * Rd(3.75%) * (1-Tc(0.14)))
Discount Rate = 5.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.53 | Cagr: -1.55%
[DCF] Terminal Value 75.24% ; FCFF base≈4.24b ; Y1≈4.21b ; Y5≈4.35b
[DCF] Fair Price = 94.61 (EV 67.8b - Net Debt -16.9b = Equity 84.7b / Shares 895.2m; r=8.35% [WACC [floored]]; 5y FCF grow -1.47% → 2.50% )
EPS Correlation: 96.70 | EPS CAGR: 13.26% | SUE: 1.21 | # QB: 5
Revenue Correlation: -10.34 | Revenue CAGR: -1.24% | SUE: 0.84 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.44 | Chg30d=-0.71% | Revisions=+25% | Analysts=12
EPS current Year (2026-12-31): EPS=5.73 | Chg30d=-0.07% | Revisions=+40% | GrowthEPS=+13.8% | GrowthRev=-6.6%
EPS next Year (2027-12-31): EPS=6.37 | Chg30d=+0.19% | Revisions=+0% | GrowthEPS=+11.2% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +38% (up=4, down=1)